Shares of Voyager Therapeutics Inc (NASDAQ:VYGR) have received an average rating of “Buy” from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $32.14.
Several analysts have recently issued reports on the stock. BTIG Research reissued a “buy” rating and issued a $32.00 price target on shares of Voyager Therapeutics in a research report on Monday, September 10th. Morgan Stanley reissued an “equal weight” rating and issued a $27.00 price target on shares of Voyager Therapeutics in a research report on Monday, September 10th. Chardan Capital reissued a “hold” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday, June 21st. ValuEngine raised shares of Voyager Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. Finally, Zacks Investment Research raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th.
In other news, Director James A. Geraghty bought 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were acquired at an average price of $19.39 per share, with a total value of $58,170.00. Following the acquisition, the director now owns 76,588 shares of the company’s stock, valued at approximately $1,485,041.32. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Glenn Pierce bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 12th. The shares were purchased at an average cost of $18.44 per share, for a total transaction of $92,200.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 11,000 shares of company stock worth $205,300 in the last ninety days. 33.60% of the stock is currently owned by insiders.
Shares of NASDAQ VYGR traded down $0.86 during midday trading on Thursday, hitting $15.15. The company’s stock had a trading volume of 332,800 shares, compared to its average volume of 410,860. Voyager Therapeutics has a one year low of $11.54 and a one year high of $31.91. The firm has a market cap of $613.69 million, a P/E ratio of -5.77 and a beta of 2.94.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.13). Voyager Therapeutics had a negative net margin of 731.88% and a negative return on equity of 80.68%. The business had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.00 million. As a group, equities research analysts expect that Voyager Therapeutics will post -3.12 earnings per share for the current fiscal year.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
See Also: Why is insider trading harmful?
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.